Navigation Links
Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
Date:12/21/2010

PORTOLA VALLEY, Calif., Dec. 21, 2010 /PRNewswire/ -- A core Spectros white LED patent was validated during reexamination by the United States Patent Office, and will reissue next year.

In a reexamination of U.S. Patent No. 6,711,426, the Patent Office has affirmed that Spectros' use of White LEDs in medical spectroscopy is unique and protectable, and that certain other applications in biomedical and industrial spectroscopy devices also fall under this Spectros patent.

"This is a broad affirmation of our dominant I.P. in the white LED and broadband spectroscopy area," noted CEO David Benaron. "This will serve as the basis for our expansion into lab-on-chip devices, color sensors, spectrometers, fluorimeters, and white LED pulse and tissue oximeters."

Spectros holds one of the early White LED patents in the U.S., and the first for use in medical and industrial spectroscopy. Spectros founders began performing color analysis, oximetry, and tissue spectroscopy in the 1980s. In the 1990s they developed a series of high-efficiency, low-thermal transfer broadband illuminators, which have been incorporated into the Spectros T-Stat® and Continuum® Tissue Oximeters, the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® competes in the marketplace with INVOS® oximeters marketed by Covidien. Multiple continuations of the Spectros white LED patent family are under prosecution in the U.S., Europe, and Japan.

Spectros and its affiliates have over 80 patents issued, licensed, or filed worldwide for molecular sensing, detection, and imaging, forming one of the largest biophotonics intellectual property collections. These solid-state illuminators can be incorporated into spectroscopy equipment, lab-on-chip devices, color sensors, spectrometers, fluorimeters, pulse and tissue oximeters, and the like.

Spectros aggressively defends its technologies and products against infringement, including litigation filed against Thermo Fisher Scientific for alleged infringement in 2009.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology.  The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
2. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
3. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
4. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
5. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
6. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
7. New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products
8. Skelley Medical Working with White House and President Obama in India
9. USP Microbial Examination of Non-Sterile Products: New White Paper is Roadmap of Regulations for Manufacturers
10. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
11. AultCare/Cardiocom® White Paper Shows Telehealth Services Reduce ER Visits and Inpatient Stays for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017   Seno Medical Instruments, Inc. , the ... through the development of an opto-acoustic (OA/US) imaging device, ... as SVP of Engineering. Mr. Miller previously served as ... with headquarters in Bothell, Washington . ... career to the development of innovative medical imaging products ...
(Date:1/18/2017)... -- Tarix Orphan LLC today announced that the U.S. Food ... (RPD) designation for the company,s drug candidate TXA127 for ... rare genetic skin disorder. There are currently no approved ... care. "The RPD designation for TXA127 in ... the FDA in this indication," said Richard Franklin ...
(Date:1/18/2017)... 18, 2017 After the recent election ... use of cannabis both for medical and recreational purposes are ... open to the use of cannabis, but the focus is ... Arcview Market Research, the North American legal cannabis market posted ... previous year. The research projects sales will grow at a ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed firm ... central Maryland and the DC region, is inaugurating a charity event aimed at fighting ... year, making it the #1 killer in America. However, heart disease is largely preventable, ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, ... Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, ... endure and pass through tough times, Dr. Bernie Siegel energizes listeners to live ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
Breaking Medicine News(10 mins):